"is a treatment for such a relatively rare eye disease going to fund much else for pyc, other than share price maybe."
Andrew: two antisense RNA drugs (ASOs) have gained FDA approval: Spinraza (Biogen Inc) and Exondys 51 (Sarepta Therapeutics Inc). Spinraza is a treatment for Spinal Muscular Atrophy (SMA) which affects around 9000 individuals in the US. Treatment cost is US$750,000 in the first year and US$375,000 annually after that. Exondys 51 treats a sub-set of Duchenne Muscular Dystrophy patients and in the interview Rohan Hocking was conservative when saying it's annual treatment cost is over $500,000. Check out the link showing these two ASO drugs are in the top five most expensive drugs in the US. https://www.pharmaceutical-technology.com/features/most-expensive-drugs-us/
PYC Price at posting:
6.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)